Myriad Genetics, Inc.
MYGN
Market Cap$1.67B
Close$
$-2.60
114% downside
Current Fair Value
114% downsideOvervalued by 114% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.67 Billion |
|---|---|
| Enterprise Value | $1.57 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-3.18 |
| Beta | 1.37 |
| Outstanding Shares | 90,478,255 |
| Avg 30 Day Volume | 561,704 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.36 |
|---|---|
| PEG | 24.24 |
| Price to Sales | 2.33 |
| Price to Book Ratio | 2.33 |
| Enterprise Value to Revenue | 2.09 |
| Enterprise Value to EBIT | -10.87 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...